Stocks of Boston Scientific Corp (NYSE:BSX) traded higher last session on Wall Street, up 0.54% to $102.96.
BSX stock price is now -0.44% away from the 50-day moving average and 7.03% away from the 200-day moving average. The market capitalization of the company currently stands at $152.32B.
With the price target of $118, Leerink Partners recently initiated with Outperform rating for Boston Scientific Corp (NYSE: BSX). On April 16, 2025, Needham Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $113, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Fitzgerald Joseph Michael, EVP & Group Pres, Cardiology sold 50,000 shares of the company’s stock on Jul 01 ’25. The stock was sold for $5,348,315 at an average price of $106.97. Upon completion of the transaction, the EVP & Group Pres, Cardiology now directly owns 178,342 shares in the company, valued at $18.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01 ’25, Officer JOSEPH M FITZGERALD bought 50,000 shares of the business’s stock. A total of $5,348,310 was incurred on buying the stock at an average price of $106.97. A total of 0.40% of the company’s stock is owned by insiders.
During the past 12 months, Boston Scientific Corp has had a low of $71.88 and a high of $107.53. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 1.45, and a quick ratio of 0.88. According to the stock market information, the enterprise value for the company is $170123329536, which is based on a 75.44 price-to-earnings ratio, a 5.37 price-to-earnings-growth ratio, and a beta of 0.67. The fifty day moving average price for BSX is $103.4196 and a two-hundred day moving average price translates $96.1987 for the stock.
The latest earnings results from Boston Scientific Corp (NYSE: BSX) was released for 2025-03-31. The net profit margin was 11.58% and return on equity was 9.65% for BSX. The company reported revenue of $4.66 billion for the quarter, compared to $3.86 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 20.93 percent.
